Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Abbott introduces new HPV infection test in Europe
The CE-marked assay can identify patients infected with specific viral genotypes known to pose the highest risk for progression to cervical cancer, said Abbott. The new assay uses
The CE-marked assay can identify patients infected with specific viral genotypes known to pose the highest risk for progression to cervical cancer, said Abbott. The new assay uses
The milestone payment of E2.5 million was triggered by enrolling the seventh patient in the multinational Fentanyl Taifun Phase III program in late December 2008. Enrollment is ongoing
The JZP-6 Phase III clinical trial program includes two randomized, double-blind, placebo-controlled studies. The first study was completed and positive top-line results were announced in November 2008. The
The agreement is Burnham’s first broad-based partnership with a large pharmaceutical company. Under this multi-year agreement, Burnham will provide Johnson & Johnson Pharmaceutical R&D (J&JPRD) with access to
The partnership between PRA Taiwan, the Taiwanese subsidiary of PRA International, Mediscience and LSK encompasses the joint management of multinational clinical trials in Asia as well as related
Schering-Plough will also collaborate with Symyx to develop within the Symyx Notebook a commercial metrology module built on the Symyx Lab Operational Informatics platform. The metrology module will
Viprinex was recently studied in a clinical trial to determine whether it was effective in improving patient outcome when given within six hours of a stroke, but the
Ms Miller has held senior positions in business development, including the title of vice president, in various companies including Anesiva, Theravance, Scios Pharmaceuticals, Onyx Pharmaceuticals and Procter &
Following clearance of the investigational new drug (IND) application by the FDA, Pluristem will initiate Phase I dose ranging clinical trials during the first half of 2009 at
The PER.C6 platform allows ProFibrix to manufacture recombinant human fibrinogen at levels that support the development and commercial rollout of new products. The company’s lead product Fibrocaps is